Recently, many Bayesian methods have been developed for dose-finding when simultaneously modeling both toxicity and efficacy outcomes in a blended phase I/II fashion. A further challenge arises when all the true efficacy data cannot be obtained quickly after the treatment, so that surrogate markers are instead used (e.g, in cancer trials). We propose a framework to jointly model the probabilities of toxicity, efficacy and surrogate efficacy given a particular dose. Our trivariate binary model is specified as a composition of two bivariate binary submodels. In particular, we extend the bCRM approach [1], as well as utilize the Gumbel copula of Thall and Cook [2] . The resulting trivariate algorithm utilizes all the available data at any given time point, and can flexibly stop the trial early for either toxicity or efficacy. Our simulation studies demonstrate our proposed method can successfully improve dosage targeting efficiency and guard against excess toxicity over a variety of true model settings and degrees of surrogacy.
Introduction
In traditional phase I clinical trials, we seek the maximum tolerated dose (MTD) of an investigational agent, which represents the highest dose with toxicity probability less than a physician-specified acceptable maximum. Based on the estimated MTD from a phase I trial, a phase II trial may be conducted to test the agent's efficacy and possibly refine the optimal dosage for futher studies. There are two general classes of phase I clinical trial designs based on dose assignment: rule-based designs, and model-based designs [3] . Rule-based designs include pharmacologically two-stage designs [4] , and the traditional 3+3 design [5] and its variations. Among model-based designs, the continual reassessment method, or CRM [6] , is a Bayesian design that has been repeatedly shown to have better operating characteristics than rule-based designs. The CRM links the true toxicity probabilities and dose levels through a simple one-parameter model, and updates the posterior estimates of the MTD arising from this parameter continuously as patients are enrolled.
The bCRM method and its extension
We now briefly mention a few recent extensions to the CRM, especially those designed to handle multiple outcomes. Braun [1] extended to a bivariate CRM (bCRM) design by constructing a conditional probability model for both efficacy and toxicity. Thall and Cook [2] jointly modeled efficacy and toxicity using a bivariate Gumbel copula [7] and introduced an efficacy-toxicity trade-off contour in two-dimensional space to guide dosage selection. Bekele and Shen [8] established a probit model with latent variables to jointly investigate a binary and a continuous outcome. Zhang et al. [9] extended the CRM to a "TriCRM" which is actually univariate but redefines the bivariate binary outcome to a trivariate one: no efficacy or toxicity, efficacy without toxicity, and toxicity with or without efficacy.
Nonparametric dose-finding methods have also been proposed to avoid the rigid functional form between the dose and true probability of toxicity or efficacy; see for example Gasparini and Eisele [10] and Yin et al. [11] .
Phase I designs that consider efficacy and toxicity rely on the timely availability of the efficacy and toxicity outcomes. In practice, it is not uncommon for toxicity to be available in a short timeframe, while a relatively long wait is required to observe efficacy. A possible solution to this problem is the use of surrogate markers as end points for efficacy. A surrogate marker is defined as a "laboratory measurement or physical sign that is used in therapeutic trials as a substitute for a clinically meaningful endpoint, that is a direct measure of how a patient feels, functions, or survives and is expected to predict the effect of the therapy" [12] . For instance, in cancer trials efficacy may be defined as a survival outcome after some fairly long period of time, say 5 years. In such cases, surrogate markers, such as a seriological measure a physician might check soon after treatment administration, are commonly used for guiding decisions about whether the intervention is promising enough to justify a large definitive trial with clinically meaningful outcomes [13] .
A fairly common situation in oncology is when toxicity and surrogate efficacy may be obtained quickly, whereas only part or none of the final efficacy data might be available. One possible solution is to simply replace the missing efficacy data with the surrogate efficacy data in our analysis. However, this could be misleading in the case of a weak surrogate; the mixture of the efficacy and surrogate efficacy data might lead to incorrect conclusions since the primary and surrogate endpoints may react quite differently to the drug. In such settings, more sophisticated biostatistical methods are needed to properly utilize all available information.
Motivating Example
We motivate our design by a Phase I dose-escalation study to evaluate a novel NK cell treatment for patients with non-Hodgkin lymphoma. The goal of this study is to evaluate the safety of the treatment, and to identify an optimal dose for further evaluation in Phase II. Unlike standard chemotherapeutic agents, we anticipate that there is a dose where further escalation would increase the probability of toxicity without a corresponding increase in the probability of efficacy. In this sense, the optimal dose for further investigation in Phase II is likely to be less than the MTD, and we must consider the tradeoff between efficacy and toxicity during dose escalation.
As is typical in phase I, efficacy and toxicity are evaluated as dichotomous outcomes. In our case, toxicity is defined as any grade 3 or higher toxicity during the first 42 days, and efficacy is defined as tumor response at day 100. The timing of these outcomes poses an obvious problem. The nearly two month delay between evaluation of the toxicity and efficacy endpoints would delay enrollment of new cohorts, and increase the overall length of our study to a point where the design is no longer practical.
Fortunately, in addition to the efficacy and toxicity outcomes, a surrogate for efficacy will be measured at day 14. One approach to overcoming the long delay between the evaluation of toxicity and the evaluation of efficacy is thus to consider the surrogate endpoint in place of the efficacy endpoint, but this could lead to incorrect conclusions about the efficacy of our drug if the surrogate endpoint does not predict true efficacy as well as anticipated. Ideally, we would prefer a dose-escalation study that makes use of the surrogate endpoint but also incorporates efficacy information as it becomes available.
In this paper, we propose a framework to jointly model the probabilities of toxicity, efficacy and surrogate efficacy given a specific dose. Our trivariate binary model is specified as a composition of two bivariate binary submodels. In particular, we extend the bCRM approach, as well as utilize the Gumbel copula of Thall and Cook [2] . The full Bayesian design consists of three elements: a trivariate binary model, a set of sensible prior distributions, and a dose-finding algorithm. Given these elements, we can repeatedly generate artificial data from our design, and thus simulate its (Bayesian or frequentist) operating characteristics, notably the empirical probabilities of correct dose selection, and the proportions of trial participants assigned to each dose.
The rest of the article is organized as follows. In Section 2 we present our general framework for the trivariate probability model, and our two preferred prametric model specifications. Bayesian prior selection and a dose-finding algorithm are addressed as well. Section 3 presents our simulation results under different scenarios, and provides guidance on specifying a future design. Finally, in Section 4 we discuss the strengths and limitations of our proposed method, and discuss areas for further investigation.
Methods

Trivariate Probability Model
Let Y ij = (T ij , S ij , E ij ) be the binary indicators of toxicity (T ), surrogate efficacy (S), and efficacy (E) for subject i who receives a drug treatment at dose X j . The joint trivariate distribution can be decomposed into three parts as (1) where t, e and s ∈ {0, 1}. If we assume conditional independence of S and T given E, the above joint distribution can be simplified to
Although this conditional independence assumption may initially seem a bit strong, note that we do not assume marginal independence of S and T ; only that their correlation is accounted for by E. Moreover, our model is consistent with the following latent process that might plausibly generate the trivariate binary outcomes:
Toxicity ⇒ Efficacy ⇒ Surrogate efficacy
In this way, the trivariate joint distribution can be represented as a product of one marginal distribution for T and two conditional distributions for E and S respectively. Therefore we can flexibly apply various parametric link functions for the marginal or conditional submodels, as we now describe.
Parametric Functions of Submodels
To monitor the marginal probabilities of T , E and S (p T j , p Ej and p Sj respectively) given dose X j , we apply three simple logistic regression models as follows:
and log
where α T , α S and α E are assumed to be negative to account for the small probabilities, while β T , β S and β E are assumed to be positive, since both efficacy and toxicity are assumed certain to be increasing with dose. This parametric model is commonly seen in many phase I designs, which assumes a monotonic relationship between dose levels and outcomes.
It is more complicated once we involve the two conditional probabilities (P r(
and P r(S ij = s | E ij = e)). For a bivariate binary distribution, we investigate approaches endorsed by Braun [1] and Thall and Cook [2] , respectively. Suppose Z 1 , Z 2 ∈ {0, 1} are two binary random variables. Based on the work of Arnold and Strauss [14] , Braun [1] suggests the following copula model for the conditional probability of Z 1 given Z 2 , namely a Bernoulli with success probability
Note this reduces to p 1 when Z 2 = 0 and
Here, ϕ captures the association between Z 1 and Z 2 , with ϕ = , clarifying the independence case. A drawback to this specification is that the joint bivariate distribution of Z 1 and Z 2 is not available as a standard family. Still, this model specification can often lead to trial designs with good operating characteristics. To adapt it to our framework, we need only set Z 1 as E and Z 2 as T to establish P r(E|T ), say with association parameter ϕ 1 . Similarly, an association parameter ϕ 2 can be used in a conditional model for P r(S|E). This extension of Braun's method is denoted by "ExB"(extended Braun) method in this paper.
Another approach to studying bivariate binary outcomes is the Gumbel copula utilized by Thall and Cook [2] . The joint bivariate Gumbel copula distribution is specified as
where p 1 and p 2 are the marginal probabilities success for Z 1 and Z 2 , respectively; note that their interpretations have changed somewhat from p 1 and p 2 in the Braun model. Similar to ϕ, γ captures the association between Z 1 and Z 2 , but now where the range of γ covers the whole real line and γ = 0 corresponds to independence, which is immediately apparent from (7) . Positive values of γ indicate positive association, while negative values imply negative association. Then the conditional probability of Z 1 given Z 2 can be easily calculated as
which is distinct from (6); in particular we note the dependence on p 2 . In the same fashion as our previous model extension, two association parameters γ 1 and γ 2 can be used in the two required conditional probabilities P r(E|T ) and P r(S|E). We refer to this extension of the Gumbel copula as the "ExG"(extended Gumbel) method in what follows.
Likelihood and Prior Specification
As with all Bayesian analyses, a full likelihood and a prior distribution for every parameter are required.
Following Braun [1] , α T , α E and α S in equations (3), (4) and (5) are all set equal to the constant −3, to reflect the relative rarity of response. Suppose that n j patients are treated at dose X j (j = 1, . . . , k), among which n tes j patients have outcomes T = t, E = e and S = s. Then the likelihood for the "ExB" model is multinomial,
where π tes j represents the joint probability of T , E, and S given dose X j , and (ϕ 1 , ϕ 2 ) is replaced by (γ 1 , γ 2 ) in the "ExG" model. The joint probabilities π tes j are computed as described in the previous two subsections. Turning to the priors, we assume β T , β S and β E all independently follow exponential distributions with mean 1. In the "ExB" method, ϕ 1 is assumed to follow a Beta(2, 2) distribution and ϕ 2 a Beta(4, 2) distribution, which encourages prior independence between E and T , but positive dependence a priori between E and S. In the "ExG" method, the priors for γ 1 and γ 2 are set as normal distributions (N (0, 5) and N (0.69, 5), respectively), priors designed to match the two beta priors as closely as possible, but on the γ scale.
Dose-Finding Algorithm
Suppose at a specific enrollment time point, Y denotes all the available accumulated data. 
the Euclidean distance between the current estimates and some physician-specified target rates of toxicity and efficacy, p * T and p * E . Here we propose a few modifications of this basic approach. First, to discourage excessive toxicity caused by high doses, we put higher weight on the toxicity component contribution to (9) . Second, we permit different penalties for over and under-dosing by incorporating asymmetry into the distance calculation. Specifically, we let
and
where 0 < w T < 1 and 0 < w E < 1. The full distance for a specific dose X j is then a modified version of (9), namely
where W dT > 0 and W dE > 0 are positive weights that can be adjusted to achieve better operating characteristics for the trial. A dose with a smaller value of dist j is more desirable since it is closer to the pre-specified probabilities of toxicity and efficacy. Finally, we also employ termination rules to control overtoxicity and to enable an early decision regarding the optimal dosage. First, if for the lowest dose level X 1 , the posterior samples of p T 1 satisfy
whereπ T is some pre-specified small value (say, 0.2), then we will terminate the trial for over-toxicity.
Second, if for some dose X j , the posterior samples of p T j and p Ej satisfy
whereπ T andπ E are two pre-specified large probabilities (say, 0.8), then we will stop the trial and define dose X j as the optimal dose. If there are multiple doses which satisfy both probability statements, then the dose with the smallest dist j in (12) is picked as the optimal dose.
In summary, our proposed trivariate dose-finding algorithm is as follows:
Trivariate Dose-finding Algorithm 1. Treat the first cohort patients at the lowest dose level.
2. Update the posterior distributions of the probabilities of toxicity and efficacy at all dose levels.
3. Calculate the criteria to check for early trial termination.
4. If not terminated, calculate the distances dist j for j = 1, . . . , 5.
5. Treat the next patient cohort at the dose having the minimum distance (12) under the restrictions of no dosage shift of more than one level of escalation or deescalation.
Repeat from
Step 2 until the trial is terminated early or maximum sample size is achieved.
Simulation Results
We now present the result of several simulation studies based on the motivating example in Section 1.2.
Throughout, we assume the times to obtain the surrogate efficacy and toxicity information for each patient are 2 days and 6 days, respectively. Rather than select an overly long wait time to observe the true efficacy endpoint, we use 15 days as the wait time in our simulations. Since the patient enrollment plan assumes we enroll a new cohort with sample size c = 3 every 6 days, this implies that at the enrollment time of the mth (m ≥ 3) cohort, the efficacy data of the (m − 2)th and (m − 1)th cohorts are unavailable. The maximum number of cohorts, L, is set to 11. The quality of surrogate marker in our models can be evaluated in two ways: the difference between S and E in marginal posterior probability, or via the association parameters (ϕ 2 or γ 2 ) between S and E. We define a "good" surrogate as one that has a strong association and a marginal probability close to that for true efficacy, while a "bad" surrogate has a weak association and a dissimilar marginal probability. To model the false positivity of the surrogate in a real situation, we set P r(S = 1) = 1.1 * P r(E = 1) for a "good" surrogate, and P r(S = 1) = 1.5 * P r(E = 1) for a "bad" surrogate. Note all of our ϕ 1 and γ 1 settings imply modest positive association between E and T , whereas the "bad" surrogate choices for ϕ 2 and γ 2 assume independence of E and S. We set w E = w T = 1 3 as our penalty reduction for undershooting toxicity and overshooting efficacy in (10) and (11), and set W dT = 2 but W dE = 1 in (12), thus making toxicity twice as important as efficacy in the distance calculation.
For our simulation, we considered both our trivariate joint models (ExB and ExG) and the corresponding bivariate models (Braun and Gumbel) that simply replaced the efficacy data with the surrogate efficacy data, assuming the latter to be without error (as is sometimes done in practice).
Due to the different meanings of ϕ 1 and γ 1 (and ϕ 2 and γ 2 ), we primarily seek to compare ExB to Braun and ExG to Gumbel, respectively, to evaluate the benefits of our trivariate model. Each of our simulation studies used 1000 simulated trials, each analyzed by generating two MCMC chains in the WinBUGS software (www.mrc-bsu.cam.ac.uk/bugs/welcome.shtml). We ran 1000 MCMC iterations after a 1000-iteration burn-in period for each chain. Standard convergence diagnostics [15] did not reveal significant MCMC convergence issues. Table 1 presents the parameter settings for Scenario 1, for which we have set Dose 4 as the optimal dose. Table 2 shows the empirical selection probabilities and percents of patients treated at each dose for the competing methods under "good" surrogacy, while Table 3 does the same for "bad" surrogacy.
Under "good" surrogacy, ExB and ExG identify the correct dose (4) more often than the Braun and Gumbel models, respectively. Both trivariate models are also substantially better under the "bad" surrogacy scenario than the corresponding bivariate models. The standard Braun and Gumbel models select the correct dose in only 21% and 26% of the simulated studies, compared to 42% and 47% for ExB and ExG, respectively. No early terminations due to over-toxicity were detected in this scenario. Table 4 describes a second scenario where Dose 2 is optimal. Results for all methods under the "good" and "bad" surrogacy cases are shown in Tables 5 and 6 , respectively. Comparing ExB and ExG to their corresponding bivariate models (Braun and Gumbel), our proposed trivariate models always have better operating characteristics under the "good" and "bad" surrogacy scenarios. Specifically, under "bad" surrogacy, the probability of selecting the correct dose increases from 62% with the Braun model to 76% with ExB and 45% with the Gumbel model to 71% with ExG. Like the first scenario, the stopping probabilities due to over-toxicity were very close to 0 (less than 2%), and therefore are omitted from the tables.
Next, we considered a scenario in which all doses are over-toxic; see Table 7 for these parameter settings. In this scenario, the probability of toxicity for all doses exceeds the physician-specified target (p * T = 0.4) and the correct decision is to terminate early. The results are shown in Tables 8 and 9 , which suggests our trivariate models can do as well as bivariate models in stopping the trial early due to over-toxicity with a high probability. Surprisingly, ExB and Braun work much better than ExG and Gumbel, stopping the trial early at least 79% of the time. In the "good" surrogacy scenario, the average numbers of patients treated under the ExB, Braun, ExG and Gumbel models are 15.1, 15.1, 23.7 and 23.9, respectively, far below the number of the patients in the initial enrollment plan (3*11=33). Note that the average number of patients treated at each dose can also be calculated. For example, Table 8 reveals there were 15.1 × 0.14 ≈ 2.1 patients actually treated at Dose level 2 on average by the ExB model. Under "bad" surrogacy, the total average numbers of patients treated under the four methods changes only slightly to 15.1, 14.8, 23.3 and 23, respectively.
We also considered varying the weights w T , w E , W dT and W dE . For example, if we set all the weights equal under scenario 1, the targeting efficiency still improves for our trivariate models (results not shown). But we might expect this may lead to a slightly higher probability of overdose (Dose 5)
than that of our weighted version. In practice, we suggest calibrating the weights to the desired level of overdose control.
Discussion
Our proposed method can successfully improve phase I/II dosage targeting efficiency by jointly modeling toxicity, efficacy and surrogate efficacy. Firstly, whether under "good" or "bad" surrogacy scenarios, the targeting performance is improved by adding some efficacy data, as opposed to using only the surrogate data. The quality of surrogate markers is an important factor in finding an optimal dosage.
In the above simulation studies, we assume a higher marginal probability for the surrogate marker, which reflects reality in the use of surrogate markers. When we use only the surrogate efficacy data, as we expect, this makes the final dose more variable, hence a poorer estimate of the optimal dose.
Especially under "bad" surrogacy, we modeled a large probability of false positive efficacy, leading to a downward effect in the dose selected. However, with some efficacy data, our joint models can eliminate part of the mean squared error and improve targeting accuracy.
Secondly, our dose finding methods perform better in a trial with a good surrogate than with a bad surrogate, which is consistent with intuition as well as efforts to find a good surrogate in clinical research. Thirdly, penalty weights w T , w E , W dT and W dT in our models can be flexibly adjusted to obtain an optimal dose under different conditions; we suggest putting more weight on w T and/or W dT to control over-toxicity. We also want to point out that direct comparison of the performance of the ExB and ExG methods might not be sensible, since the interpretation of association parameters ϕ or γ is different in each model and it is thus unclear how fair comparisons can be made.
Our setting is just an idealization of actual practice, and could be modified. For example, the use of the rigid logistic function of form with intercept fixed at −3 could be replaced with other parametric or nonparametric forms for the oxicity, efficacy, or surrogate efficacy probabilities [16, 17, 18] . Adding an upper bound θ < 1 on the probability of efficacy (or surrogate efficacy) may also be sensible.
Another extension of our method could be to jointly model several surrogate markers for toxicity and efficacy. All the surrogate markers could be assumed to be operate in "parallel", meaning that all their inter-connections are captured conditional on efficacy. As mentioned in Section 2.1, the assumption of conditional independence of toxicity and surrogate toxicity assumption might be too strong. Exploration of the relationship between T , E and S (or multiple Ss) may shed light on this issue.
We also tried to detect the association between toxicity, efficacy and surrogate efficacy by posterior samples of related association parameters. Unfortunately, this estimation was not satisfactory, with large posterior variance. The reason might be that we are trying to estimate a fairly data-insensitive parameter with too small a sample size of binary outcomes that themselves contain little information about the association parameter. Finally, our definition of a "good" or "bad" surrogate is a little arbitrary. A better quantification of the quality of surrogacy and its effect on our dose-finding are another subject for future investigation.
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